The European Medicines Agency proposed a centralized contract platform and template resources to help sponsors and CROs negotiate EU clinical trial agreements more efficiently. In its clinical trial highlights newsletter, the agency said contractual negotiations remain a major bottleneck delaying trial start-up, pointing to persistent variability across member states. EMA highlighted that existing templates often do not account for multi-country, multi-site trials spanning several EU member states. The proposed approach aims to share best practices and standardize common contracting issues while maintaining representation from relevant stakeholders. Industry groups including EFPIA and EUCROF supported faster site contracting processes, aligning with continued pressure to reduce administrative delays as EU enrollment and operational capacity are stretched.